Table 2 List of identified beneficial overlapping peptides (OLP, PR > 1) incorporated in the final T-cell immunogen design, based on previous analysis [28]
OLP no. | Protein | Subunit | OLP clade B cons sequence |
|---|---|---|---|
3 | Gag | p17 | EKIRLRPGGKKKYKLKHI |
6 | Gag | p17 | ASRELERFAVNPGLL |
7 | Gag | p17 | ERFAVNPGLLETSEGCR |
10 | Gag | p17 | QLQPSLQTGSEELRSLY |
12 | Gag | p17 | SLYNTVATLYCVHQRIEV |
23 | Gag | p24 | AFSPEVIPMFSALSEGA |
31 | Gag | p24 | IAPGQMREPRGSDIA |
34 | Gag | p24 | STLQEQIGWMTNNPPIPV |
48 | Gag | p24 | ACQGVGGPGHKARVLAEA |
60 | Gag | p15 | GKIWPSHKGRPGNFLQSR |
75 | Nef | - | WLEAQEEEEVGFPVRPQV |
159 | Pol | Prt | KMIGGIGGFIKVRQYDQI |
160 | Pol | Prt | FIKVRQYDQILIEICGHK |
161 | Pol | Prt | QILIEICGHKAIGTVLV |
163 | Pol | Prt | LVGPTPVNIIGRNLLTQI |
171 | Pol | RT | LVEICTEMEKEGKISKI |
195 | Pol | RT | LRWGFTTPDKKHQKEPPF |
196 | Pol | RT | DKKHQKEPPFLWMGYELH |
210 | Pol | RT | EIQKQGQGQWTYQIY |
269 | Pol | Int | TKELQKQITKIQNFRVYY |
270 | Pol | Int | TKIQNFRVYYRDSRDPLW |
271 | Pol | Int | YYRDSRDPLWKGPAKLLW |
276 | Pol | Int | KIIRDYGKQMAGDDCVA |
405 | Vif | - | VKHHMYISGKAKGWFYRH |
406 | Vif | - | GKAKGWFYRHHYESTHPR |
424 | Vif | - | TKLTEDRWNKPQKTKGHR |